Latest News from Origin
Scancell realisation – 5.5x money
Scancell develops DNA-based vaccines for cancer therapy, and potentially other indications. We invested in the company in three separate funding rounds, in 2008, 2010 and 2011. We sold our holding in the latter half of 2015, realising just over 5.5x cost, equating to an IRR over the life of the investment of 37% pre-EIS benefits, or 44% including them.
Naturemetrics – New investment in genetic environmental monitoring
Naturemetrics is using DNA and other genetic approaches to assess the presence of organisms in natural environments. We have participated in a seed-funding round alongside the Iceni seedcorn fund and several individual angel investors.
Co-invest with Origin
Please contact us if you would like to discuss co-investing in our transactions. (Note: currently only possible in unquoted investments, although we hope shortly to be able to offer quoted company co-investment also.)
Trakm8 – New AIM investment
Trakm8 provides vehicle telematics solutions for fleet operators and insurance company clients. We believe this market has significant growth potential and that Trakm8 has a strong competitive position and an impressive senior team.
Monica Healthcare: Strong progress and follow-on investment
We are delighted that since our original 2015 investment, Monica has agreed important commercial partnerships with GE Healthcare and Philips Health. These are the largest global suppliers of equipment in Monica’s clinical field of labour monitoring. We have recently participated in a top-up investment round.
1Spatial – New AIM investment
1Spatial is an AIM-quoted business that has developed sophisticated software used in geospatial data management. We are impressed by the quality and competitive strength of the company’s technology, and the potential of its commercial partnerships, and have recently invested in the company.
SRT – Major contract win
We invested in AIM-quoted SRT in mid 2015 and were very pleased to note the company’s recent announcement of a major Asian contract, worth an estimated $90m over three years. We believe there will be further deals of this type, which could be transformational for the business.
New investment – Desktop Genetics
We are delighted to have participated in a seed funding round for Desktop Genetics. The company produces software used in the design and execution of genome editing experiments, a market that is experiencing enormous growth. The company’s core platform, DESKGEN, is used with the world-leading CRISPR/Cas editing technology.
Origin Capital Q2 2015 News
Please click here to read a round up of our latest news.
Co-invest with Origin Capital – update!
We are pleased to announce that we have recently been accepted as an Appointed Representative of Larpent Newton Ltd, which is authorised and regulated by the Financial Conduct Authority (“FCA”). This new status means we are now able to offer third parties the opportunity to co-invest in our transactions.